These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25956450)

  • 1. Novel missense mutations in PNPLA2 causing late onset and clinical heterogeneity of neutral lipid storage disease with myopathy in three siblings.
    Missaglia S; Tasca E; Angelini C; Moro L; Tavian D
    Mol Genet Metab; 2015; 115(2-3):110-7. PubMed ID: 25956450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of novel ATGL missense mutations to the clinical phenotype of NLSD-M: a strikingly low amount of lipase activity may preserve cardiac function.
    Tavian D; Missaglia S; Redaelli C; Pennisi EM; Invernici G; Wessalowski R; Maiwald R; Arca M; Coleman RA
    Hum Mol Genet; 2012 Dec; 21(24):5318-28. PubMed ID: 22990388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A myopathy with unusual features caused by PNPLA2 gene mutations.
    Pennisi EM; Missaglia S; Dimauro S; Bernardi C; Akman HO; Tavian D
    Muscle Nerve; 2015 Apr; 51(4):609-13. PubMed ID: 25287355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late onset of neutral lipid storage disease due to novel PNPLA2 mutations causing total loss of lipase activity in a patient with myopathy and slight cardiac involvement.
    Missaglia S; Maggi L; Mora M; Gibertini S; Blasevich F; Agostoni P; Moro L; Cassandrini D; Santorelli FM; Gerevini S; Tavian D
    Neuromuscul Disord; 2017 May; 27(5):481-486. PubMed ID: 28258942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic lipid storage in carriers for the PNPLA2 gene.
    Janssen MC; van Engelen B; Kapusta L; Lammens M; van Dijk M; Fischer J; van der Graaf M; Wevers RA; Fahrleitner M; Zimmermann R; Morava E
    Eur J Hum Genet; 2013 Aug; 21(8):807-15. PubMed ID: 23232698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phenotypic spectrum of neutral lipid storage myopathy due to mutations in the PNPLA2 gene.
    Reilich P; Horvath R; Krause S; Schramm N; Turnbull DM; Trenell M; Hollingsworth KG; Gorman GS; Hans VH; Reimann J; MacMillan A; Turner L; Schollen A; Witte G; Czermin B; Holinski-Feder E; Walter MC; Schoser B; Lochmüller H
    J Neurol; 2011 Nov; 258(11):1987-97. PubMed ID: 21544567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mutation in PNPLA2 leading to neutral lipid storage disease with myopathy.
    Ash DB; Papadimitriou D; Hays AP; Dimauro S; Hirano M
    Arch Neurol; 2012 Sep; 69(9):1190-2. PubMed ID: 22964912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel PNPLA2 gene mutation in a child causing neutral lipid storage disease with myopathy.
    Zheng S; Liao W
    BMC Med Genet; 2018 Sep; 19(1):172. PubMed ID: 30223778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel mutation in PNPLA2 causes neutral lipid storage disease with myopathy and triglyceride deposit cardiomyovasculopathy: a case report and literature review.
    Kaneko K; Kuroda H; Izumi R; Tateyama M; Kato M; Sugimura K; Sakata Y; Ikeda Y; Hirano K; Aoki M
    Neuromuscul Disord; 2014 Jul; 24(7):634-41. PubMed ID: 24836204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel duplication mutation in the patatin domain of adipose triglyceride lipase (PNPLA2) in neutral lipid storage disease with severe myopathy.
    Akiyama M; Sakai K; Ogawa M; McMillan JR; Sawamura D; Shimizu H
    Muscle Nerve; 2007 Dec; 36(6):856-9. PubMed ID: 17657808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel PNPLA2 gene mutations in Chinese Han patients causing neutral lipid storage disease with myopathy.
    Lin P; Li W; Wen B; Zhao Y; Fenster DS; Wang Y; Gong Y; Yan C
    J Hum Genet; 2012 Oct; 57(10):679-81. PubMed ID: 22832386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutral Lipid Storage Diseases: clinical/genetic features and natural history in a large cohort of Italian patients.
    Pennisi EM; Arca M; Bertini E; Bruno C; Cassandrini D; D'amico A; Garibaldi M; Gragnani F; Maggi L; Massa R; Missaglia S; Morandi L; Musumeci O; Pegoraro E; Rastelli E; Santorelli FM; Tasca E; Tavian D; Toscano A; Angelini C;
    Orphanet J Rare Dis; 2017 May; 12(1):90. PubMed ID: 28499397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole exome sequence analysis reveals a homozygous mutation in PNPLA2 as the cause of severe dilated cardiomyopathy secondary to neutral lipid storage disease.
    Muggenthaler M; Petropoulou E; Omer S; Simpson MA; Sahak H; Rice A; Raju H; Conti FJ; Bridges LR; Anderson LJ; Sharma S; Behr ER; Jamshidi Y
    Int J Cardiol; 2016 May; 210():41-4. PubMed ID: 26922712
    [No Abstract]   [Full Text] [Related]  

  • 14. Generation of induced Pluripotent Stem Cells as disease modelling of NLSDM.
    Tavian D; Missaglia S; Castagnetta M; Degiorgio D; Pennisi EM; Coleman RA; Dell'Era P; Mora C; Angelini C; Coviello DA
    Mol Genet Metab; 2017 May; 121(1):28-34. PubMed ID: 28391974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with neutral lipid storage disease with myopathy (NLSDM) in Southwestern China.
    Tan J; Yang H; Fan J; Fan Y; Xiao F
    Clin Neurol Neurosurg; 2018 May; 168():102-107. PubMed ID: 29539587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutral lipid storage disease with myopathy and dropped head syndrome. Report of a new variant susceptible of treatment with late diagnosis.
    Garcia MA; Rojas JA; Millán SP; Flórez AA
    J Clin Neurosci; 2018 Dec; 58():207-209. PubMed ID: 30352762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PNPLA2 mutation: a paediatric case with early onset but indolent course.
    Perrin L; Féasson L; Furby A; Laforêt P; Petit FM; Gautheron V; Chabrier S
    Neuromuscul Disord; 2013 Dec; 23(12):986-91. PubMed ID: 24074500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutral lipid storage disease with myopathy: Further phenotypic characterization of a rare PNPLA2 variant.
    Latimer CS; Schleit J; Reynolds A; Marshall DA; Podemski B; Wang LH; Gonzalez-Cuyar LF
    Neuromuscul Disord; 2018 Jul; 28(7):606-609. PubMed ID: 29779757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subclinical myopathy in a child with neutral lipid storage disease and mutations in the PNPLA2 gene.
    Fiorillo C; Brisca G; Cassandrini D; Scapolan S; Astrea G; Valle M; Scuderi F; Trucco F; Natali A; Magnano G; Gazzerro E; Minetti C; Arca M; Santorelli FM; Bruno C
    Biochem Biophys Res Commun; 2013 Jan; 430(1):241-4. PubMed ID: 23146629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutral lipid storage disease: genetic disorders caused by mutations in adipose triglyceride lipase/PNPLA2 or CGI-58/ABHD5.
    Schweiger M; Lass A; Zimmermann R; Eichmann TO; Zechner R
    Am J Physiol Endocrinol Metab; 2009 Aug; 297(2):E289-96. PubMed ID: 19401457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.